Business Intelligence

A multidisciplinary task force of 14 European AI experts has come up with a set of broad guidelines for anyone using the technology to analyze big data in healthcare.

A Harvard Law School professor is warning that AI may be hazardous to the health of U.S. healthcare.

IBM, along with KPMG, Merck and Walmart have been selected by the FDA to participate in a blockchain project that aims to improve the drug supply chain.

A San Francisco-based startup that uses a proprietary machine-learning platform to identify the care needs of covered employees has raised $205 million to “address fundamental health insurance service issues that plague U.S. consumers and employers alike.”

BlackThorn Therapeutics, a clinical-stage neurobehaviorial health company, has raised $76 million in a Series B funding round, the company announced June 13.  

The American Medical Association is pushing for policies around AI in healthcare that don’t penalize physicians who avoid the technology while it’s still in a state of flux on so many fronts, from regulatory oversight to clinical usefulness.

Microsoft is launching a regional hub for AI, Internet of Things and data science in Louisville, Kentucky, according to Mayor Greg Fischer, with a focus on collaborating with partners in healthcare and manufacturing.

Retail giant Walmart has joined a blockchain group that aims to track and verify prescription drugs, the company confirmed to CoinDesk.

The vast majority of healthcare executives––89%––are experimenting with emerging technologies such as AI, according to Accenture’s Digital Health Technology Vision report.

Whether or not its pending $68 billion purchase of Aetna gets finalized, CVS Health will pump big bucks into broadening its menu of healthcare services and personalizing them for consumers. And a key component of its plan is a data-analytics strategy steeped in AI.

UCLA Health is synthesizing vast amounts of data by deploying new Microsoft cloud computing services, Microsoft Azure, that will speed up medical discoveries and improve patient care.

Tempus, a Chicago-based precision medicine company that uses machine learning, genomic sequencing and other AI innovations, has raised $200 million in a series F funding round, the company announced.